Cargando…

191例EGFR突变状态不明晚期肺腺癌患者EGFR-TKIs耐药后化疗的疗效分析

BACKGROUND AND OBJECTIVE: Subsequent chemotherapy were needed in patients with advanced pulmonary adenocarcinoma experiencing disease progression after epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. The study is to explore factors potentially influencing efficacy...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015173/
https://www.ncbi.nlm.nih.gov/pubmed/24113006
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.10.06
_version_ 1783334350558855168
collection PubMed
description BACKGROUND AND OBJECTIVE: Subsequent chemotherapy were needed in patients with advanced pulmonary adenocarcinoma experiencing disease progression after epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. The study is to explore factors potentially influencing efficacy of subsequent chemotherapy. METHODS: One hundred and ninety-one patients with advanced lung adenocarcinoma, who were resistant from EGFR-TKIs and then received subsequent chemotherapy, were identified. Data of patient's characteristics, responses to chemotherapy and survival time were analyzed retrospectively. RESULTS: The overall response rate of the pemetrexed-based chemotherapy (9.3%) was higher than non-pemetrexed-based regimen (1.1%), P=0.011. Furthermore, the response in the second-line was more obvisous [objective response rate (ORR) 14.3% vs 3.7%, P=0.041]. The patients who achieved response of partial response (PR) showed longer progression-free survival (PFS) than those who achieved non-PR (PFS 10.1 months and 2.3 months, P=0.012). The patients treated with platinum-based chemotherapy had longer PFS and OS than those with non-platinum-based chemotherapy, therefore platinum-based regimen was independent prognosis factors for PFS and OS (PFS: RR=0.634, 95%CI: 0.466-0.832, P=0.004; OS: RR=0.666, 95%CI: 0.460-0.960, P=0.030), especially the pateients who were aquired EGFR-TKIs resistance and who got drmatic progression from EGFR-TKIs treatment might got more benefits from platinum-based chemotherapy. However there was no significant difference in ORR, PFS or OS between patients with TKIs primary resistance and acquired resistance, or between dramtic progression and gradual/local progression. CONCLUSION: The patients with advanced lung adenocarcinoma might get benefits from pemetrexed-based or platinum-based chemotherapy after they were EGFR-TKIs resistace.
format Online
Article
Text
id pubmed-6015173
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60151732018-07-06 191例EGFR突变状态不明晚期肺腺癌患者EGFR-TKIs耐药后化疗的疗效分析 Zhongguo Fei Ai Za Zhi Tki耐药专题 BACKGROUND AND OBJECTIVE: Subsequent chemotherapy were needed in patients with advanced pulmonary adenocarcinoma experiencing disease progression after epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. The study is to explore factors potentially influencing efficacy of subsequent chemotherapy. METHODS: One hundred and ninety-one patients with advanced lung adenocarcinoma, who were resistant from EGFR-TKIs and then received subsequent chemotherapy, were identified. Data of patient's characteristics, responses to chemotherapy and survival time were analyzed retrospectively. RESULTS: The overall response rate of the pemetrexed-based chemotherapy (9.3%) was higher than non-pemetrexed-based regimen (1.1%), P=0.011. Furthermore, the response in the second-line was more obvisous [objective response rate (ORR) 14.3% vs 3.7%, P=0.041]. The patients who achieved response of partial response (PR) showed longer progression-free survival (PFS) than those who achieved non-PR (PFS 10.1 months and 2.3 months, P=0.012). The patients treated with platinum-based chemotherapy had longer PFS and OS than those with non-platinum-based chemotherapy, therefore platinum-based regimen was independent prognosis factors for PFS and OS (PFS: RR=0.634, 95%CI: 0.466-0.832, P=0.004; OS: RR=0.666, 95%CI: 0.460-0.960, P=0.030), especially the pateients who were aquired EGFR-TKIs resistance and who got drmatic progression from EGFR-TKIs treatment might got more benefits from platinum-based chemotherapy. However there was no significant difference in ORR, PFS or OS between patients with TKIs primary resistance and acquired resistance, or between dramtic progression and gradual/local progression. CONCLUSION: The patients with advanced lung adenocarcinoma might get benefits from pemetrexed-based or platinum-based chemotherapy after they were EGFR-TKIs resistace. 中国肺癌杂志编辑部 2013-10-20 /pmc/articles/PMC6015173/ /pubmed/24113006 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.10.06 Text en 版权所有©《中国肺癌杂志》编辑部2013 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle Tki耐药专题
191例EGFR突变状态不明晚期肺腺癌患者EGFR-TKIs耐药后化疗的疗效分析
title 191例EGFR突变状态不明晚期肺腺癌患者EGFR-TKIs耐药后化疗的疗效分析
title_full 191例EGFR突变状态不明晚期肺腺癌患者EGFR-TKIs耐药后化疗的疗效分析
title_fullStr 191例EGFR突变状态不明晚期肺腺癌患者EGFR-TKIs耐药后化疗的疗效分析
title_full_unstemmed 191例EGFR突变状态不明晚期肺腺癌患者EGFR-TKIs耐药后化疗的疗效分析
title_short 191例EGFR突变状态不明晚期肺腺癌患者EGFR-TKIs耐药后化疗的疗效分析
title_sort 191例egfr突变状态不明晚期肺腺癌患者egfr-tkis耐药后化疗的疗效分析
topic Tki耐药专题
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015173/
https://www.ncbi.nlm.nih.gov/pubmed/24113006
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.10.06
work_keys_str_mv AT 191lìegfrtūbiànzhuàngtàibùmíngwǎnqīfèixiànáihuànzhěegfrtkisnàiyàohòuhuàliáodeliáoxiàofēnxī
AT 191lìegfrtūbiànzhuàngtàibùmíngwǎnqīfèixiànáihuànzhěegfrtkisnàiyàohòuhuàliáodeliáoxiàofēnxī
AT 191lìegfrtūbiànzhuàngtàibùmíngwǎnqīfèixiànáihuànzhěegfrtkisnàiyàohòuhuàliáodeliáoxiàofēnxī
AT 191lìegfrtūbiànzhuàngtàibùmíngwǎnqīfèixiànáihuànzhěegfrtkisnàiyàohòuhuàliáodeliáoxiàofēnxī
AT 191lìegfrtūbiànzhuàngtàibùmíngwǎnqīfèixiànáihuànzhěegfrtkisnàiyàohòuhuàliáodeliáoxiàofēnxī
AT 191lìegfrtūbiànzhuàngtàibùmíngwǎnqīfèixiànáihuànzhěegfrtkisnàiyàohòuhuàliáodeliáoxiàofēnxī
AT 191lìegfrtūbiànzhuàngtàibùmíngwǎnqīfèixiànáihuànzhěegfrtkisnàiyàohòuhuàliáodeliáoxiàofēnxī
AT 191lìegfrtūbiànzhuàngtàibùmíngwǎnqīfèixiànáihuànzhěegfrtkisnàiyàohòuhuàliáodeliáoxiàofēnxī
AT 191lìegfrtūbiànzhuàngtàibùmíngwǎnqīfèixiànáihuànzhěegfrtkisnàiyàohòuhuàliáodeliáoxiàofēnxī
AT 191lìegfrtūbiànzhuàngtàibùmíngwǎnqīfèixiànáihuànzhěegfrtkisnàiyàohòuhuàliáodeliáoxiàofēnxī
AT 191lìegfrtūbiànzhuàngtàibùmíngwǎnqīfèixiànáihuànzhěegfrtkisnàiyàohòuhuàliáodeliáoxiàofēnxī
AT 191lìegfrtūbiànzhuàngtàibùmíngwǎnqīfèixiànáihuànzhěegfrtkisnàiyàohòuhuàliáodeliáoxiàofēnxī